Developing a life-saving cure for thrombosis after Astrazeneca’s Covid vaccine

A life-saving therapy for the treatment of thrombosis related to Astrazeneca’s Covid vaccine has been developed by researchers at McMaster University in Hamilton, Canada. The treatment, which consists in the administration of intravenous immunoglobulins and anticoagulants, has saved at least three patients who had recently undergone vaccination with viral vector serum, showing symptoms of vaccine-induced immune thrombocytopenia (VITT, vaccine-induced immune thrombotic thrombocytopenia), a rare condition that can affect, on average, one person in every 100,000 doses administered. Characterizing it is a series of clinical signs that may occur five to three weeks after vaccination, such as swelling of an arm or leg, abdominal pain, headache, blurred vision, dizziness, difficulty breathing, chest pain, tachycardia, bleeding and bruising .

The patients treated by the researchers, two men and one woman, aged between 63 and 72 years, quickly showed signs of improvement, starting with the restoration of the platelet count, which returned to normal levels within a few days. “Increased platelet counts are particularly important when patients have severe forms of thrombocytopenia and unusual multiple thromboses requiring a therapeutic dose of anticoagulants”Indicate the researchers who described the results of the therapy in a study published in the New England Journal of Medicine. “Because patients with VITT may have severe thrombocytopenia potentially lasting for several weeks, early intravenous administration of high-dose immunoglobulin it can be an important adjunct therapy anticoagulation for the management of VITT”.

Overall, the therapy reflects the indications of the treatment protocols published following the reporting of the first cases of VITT. However, the researchers indicate, the recommendation for early administration of immunoglobulins at a dosage of 1 g per kilogram of body weight for two consecutive days (ie a total of 2 g per kilogram) “it can be ambiguous“Because the applicable body weight”it can range from ideal to actual or an intermediate value“. Therefore, they observe on the basis of the experience gained, “we suggest the use of dosage based on minimum weight and preferably according to actual body weight in making these calculations, data dose-dependent effects immunoglobulins in decreasing antibody-induced platelet activation”.

READ ALSO:  Santiago Mayor's Office launches new pediatric health project

window._fpcmp.push(function(gdpr)
{
!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s)}(window, document,’script’,
‘https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘2062554930705272’);
fbq(‘track’, ‘PageView’);
//fbq(‘track’, ‘ViewContent’);
//send custom checkpoints event
(function () {
var checkPoints = [10, 20, 40, 60, 90, 120, 180, 240, 300].sort(function(a, b) {
return a – b;
}); //seconds
var checkPointIndex = 0;
var f = function(){
var data = {
instant: checkPoints[checkPointIndex]
};
console.log(“[FB PIXEL] send custom event ViewContentCheckPoint “, data, ” on account ” ,”2062554930705272″ , ” currentTime in seconds “,
new Date().getTime() / 1000);
fbq(‘trackCustom’, ‘ViewContentCheckPoint’, data);
checkPointIndex++;
if(checkPointIndex < checkPoints.length) {
setTimeout(f, (checkPoints[checkPointIndex] – checkPoints[checkPointIndex-1]) * 1000)
}
};
if(checkPoints.length){
setTimeout(f, checkPoints[checkPointIndex] * 1000)
}

})();
});

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more

Leave a Reply

Your email address will not be published. Required fields are marked *